OSUR OraSure Technologies Inc.

OraSure to Participate in Upcoming Investor Conference

OraSure to Participate in Upcoming Investor Conference

BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:

  • Stephens Annual Investment Conference on Wednesday, November 20, with a Q&A session scheduled for 1 p.m. ET

A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at . The webcast will be archived on OraSure’s website and will be available for approximately 90 days.

About OraSure Technologies, Inc. 

OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit .                                           

Investor Contact:

Jason Plagman 

VP, Investor Relations



Media Contact:

Amy Koch

Director, Corporate Communications



EN
18/11/2024

Underlying

OSUROraSure Technologies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OraSure Technologies Inc.

 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure Technologies Acquires Sherlock Biosciences

OraSure Technologies Acquires Sherlock Biosciences BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specif...

December 19, 2024 1 EN
 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure Receives Federal Funding for Development of Marburg Virus Rapi...

OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and R...

December 2, 2024 1 EN
 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure to Participate in Upcoming Investor Conference

OraSure to Participate in Upcoming Investor Conference BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment Conference on Wednesday, November 20, with a Q&A session scheduled for 1 p.m. ET A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at . The webcast will be archived on OraSure’s website and will be available for approximately 90 days. About OraSure Techn...

November 18, 2024 1 EN
 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure Reports Q3 ’24 Revenue of $39.9 Million

OraSure Reports Q3 ’24 Revenue of $39.9 Million Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three mon...

November 6, 2024 1 EN
 PRESS RELEASE
Free
OSUR OraSure Technol...

OraSure to Announce Third Quarter 2024 Financial Results and Host Earn...

OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webca...

October 22, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch